18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?
Purpose During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the l...
Gespeichert in:
| Veröffentlicht in: | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging 2022, Vol.10 (6), p.687-695 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 695 |
|---|---|
| container_issue | 6 |
| container_start_page | 687 |
| container_title | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging |
| container_volume | 10 |
| creator | Urso, Luca Lancia, Federica Ortolan, Naima Frapoli, Marta Rauso, Martina Artioli, Paolo Cittanti, Corrado Uccelli, Licia Frassoldati, Antonio Evangelista, Laura Bartolomei, Mirco |
| description | Purpose
During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the lack of large-scale prospective trials.
Methods
We report the cases of seven patients affected by PCa, in which [18F]F-choline PET (either with computed tomography—CT or magnetic resonance imaging—MR) contributed significantly in the systemic therapy response evaluation.
Results and conclusion
[18F]F-choline PET/CT or PET/MR demonstrated to be a useful imaging modality in the assessment of response to systemic therapy in metastatic PCa patients, irrespective of the stage of disease (either in hormone sensitive and in castrate resistant condition) and the kind of systemic treatment. In most cases, PSA serum values and [18F]F-choline PET showed a synchronous disease evolution after systemic therapy. ADT can alter [18F]F-choline uptake, therefore the time of scan should be correctly planned. Finally, PET/CT with [18F]F-choline is a useful tool for reinforcing the identification of metastatic disease in case of a switch from metastatic castration sensitive to castration resistant PCa. |
| doi_str_mv | 10.1007/s40336-022-00515-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9333077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2697676462</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-292883c6c25a61eaedd977aa195bf7f7b7f898baa9681af50978877d57e3086f3</originalsourceid><addsrcrecordid>eNp9kUlvFDEQhS0EIlHIH-BkiQuXJl7GGwcQGmVBCgKh4WzVuKszHfXYHdudaP49PZmI7cCpSqrvPVXVI-Q1Z-84Y-asLJiUumFCNIwprhrzjBwLYXljlFbP_-iPyGkpt4wxzrjinL8kR1I57qRlx-SO24tmuUlDH5F-O1-dLVc05cfuy3cKsaV1gxTvYZig9inS1NGMZUyxIK2Jll2puO3DHssw7mgf6ZhTqVCRBogB83sKGekDzjpodx9fkRcdDAVPn-oJ-XFxvlpeNddfLz8vP103YaF4bYQT1sqgg1CgOQK2rTMGgDu17kxn1qazzq4BnLYcOsWcsdaYVhmUzOpOnpAPB99xWm-xDRhrhsGPud9C3vkEvf97EvuNv0n33kkpmTGzwdsng5zuJizVb_sScBggYpqKF9oZbfRCixl98w96m6Yc5_O8MFJZJwxzMyUOVJgfVDJ2v5bhzO9D9YdQ_RyqfwzV77eQB1GZ4XiD-bf1f1Q_AZniogg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2735892709</pqid></control><display><type>article</type><title>18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?</title><source>SpringerLINK Journals</source><creator>Urso, Luca ; Lancia, Federica ; Ortolan, Naima ; Frapoli, Marta ; Rauso, Martina ; Artioli, Paolo ; Cittanti, Corrado ; Uccelli, Licia ; Frassoldati, Antonio ; Evangelista, Laura ; Bartolomei, Mirco</creator><creatorcontrib>Urso, Luca ; Lancia, Federica ; Ortolan, Naima ; Frapoli, Marta ; Rauso, Martina ; Artioli, Paolo ; Cittanti, Corrado ; Uccelli, Licia ; Frassoldati, Antonio ; Evangelista, Laura ; Bartolomei, Mirco</creatorcontrib><description>Purpose
During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the lack of large-scale prospective trials.
Methods
We report the cases of seven patients affected by PCa, in which [18F]F-choline PET (either with computed tomography—CT or magnetic resonance imaging—MR) contributed significantly in the systemic therapy response evaluation.
Results and conclusion
[18F]F-choline PET/CT or PET/MR demonstrated to be a useful imaging modality in the assessment of response to systemic therapy in metastatic PCa patients, irrespective of the stage of disease (either in hormone sensitive and in castrate resistant condition) and the kind of systemic treatment. In most cases, PSA serum values and [18F]F-choline PET showed a synchronous disease evolution after systemic therapy. ADT can alter [18F]F-choline uptake, therefore the time of scan should be correctly planned. Finally, PET/CT with [18F]F-choline is a useful tool for reinforcing the identification of metastatic disease in case of a switch from metastatic castration sensitive to castration resistant PCa.</description><identifier>ISSN: 2281-7565</identifier><identifier>ISSN: 2281-5872</identifier><identifier>EISSN: 2281-7565</identifier><identifier>DOI: 10.1007/s40336-022-00515-7</identifier><identifier>PMID: 35919380</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Choline ; Computed tomography ; Diagnostic Radiology ; Evaluation ; Fluorine isotopes ; Genitourinary ; Imaging ; Interventional Radiology ; Magnetic resonance imaging ; Medical and Radiation Physics ; Medical imaging ; Medicine ; Medicine & Public Health ; Metastasis ; Nuclear Medicine ; Pictorial ; Pictorial Essay ; Positron emission ; Prostate cancer ; Radiology ; Radiotherapy ; Therapy ; Tomography</subject><ispartof>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2022, Vol.10 (6), p.687-695</ispartof><rights>The Author(s) 2022</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-292883c6c25a61eaedd977aa195bf7f7b7f898baa9681af50978877d57e3086f3</citedby><cites>FETCH-LOGICAL-c451t-292883c6c25a61eaedd977aa195bf7f7b7f898baa9681af50978877d57e3086f3</cites><orcidid>0000-0002-5117-804X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s40336-022-00515-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s40336-022-00515-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Urso, Luca</creatorcontrib><creatorcontrib>Lancia, Federica</creatorcontrib><creatorcontrib>Ortolan, Naima</creatorcontrib><creatorcontrib>Frapoli, Marta</creatorcontrib><creatorcontrib>Rauso, Martina</creatorcontrib><creatorcontrib>Artioli, Paolo</creatorcontrib><creatorcontrib>Cittanti, Corrado</creatorcontrib><creatorcontrib>Uccelli, Licia</creatorcontrib><creatorcontrib>Frassoldati, Antonio</creatorcontrib><creatorcontrib>Evangelista, Laura</creatorcontrib><creatorcontrib>Bartolomei, Mirco</creatorcontrib><title>18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?</title><title>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</title><addtitle>Clin Transl Imaging</addtitle><description>Purpose
During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the lack of large-scale prospective trials.
Methods
We report the cases of seven patients affected by PCa, in which [18F]F-choline PET (either with computed tomography—CT or magnetic resonance imaging—MR) contributed significantly in the systemic therapy response evaluation.
Results and conclusion
[18F]F-choline PET/CT or PET/MR demonstrated to be a useful imaging modality in the assessment of response to systemic therapy in metastatic PCa patients, irrespective of the stage of disease (either in hormone sensitive and in castrate resistant condition) and the kind of systemic treatment. In most cases, PSA serum values and [18F]F-choline PET showed a synchronous disease evolution after systemic therapy. ADT can alter [18F]F-choline uptake, therefore the time of scan should be correctly planned. Finally, PET/CT with [18F]F-choline is a useful tool for reinforcing the identification of metastatic disease in case of a switch from metastatic castration sensitive to castration resistant PCa.</description><subject>Choline</subject><subject>Computed tomography</subject><subject>Diagnostic Radiology</subject><subject>Evaluation</subject><subject>Fluorine isotopes</subject><subject>Genitourinary</subject><subject>Imaging</subject><subject>Interventional Radiology</subject><subject>Magnetic resonance imaging</subject><subject>Medical and Radiation Physics</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastasis</subject><subject>Nuclear Medicine</subject><subject>Pictorial</subject><subject>Pictorial Essay</subject><subject>Positron emission</subject><subject>Prostate cancer</subject><subject>Radiology</subject><subject>Radiotherapy</subject><subject>Therapy</subject><subject>Tomography</subject><issn>2281-7565</issn><issn>2281-5872</issn><issn>2281-7565</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><recordid>eNp9kUlvFDEQhS0EIlHIH-BkiQuXJl7GGwcQGmVBCgKh4WzVuKszHfXYHdudaP49PZmI7cCpSqrvPVXVI-Q1Z-84Y-asLJiUumFCNIwprhrzjBwLYXljlFbP_-iPyGkpt4wxzrjinL8kR1I57qRlx-SO24tmuUlDH5F-O1-dLVc05cfuy3cKsaV1gxTvYZig9inS1NGMZUyxIK2Jll2puO3DHssw7mgf6ZhTqVCRBogB83sKGekDzjpodx9fkRcdDAVPn-oJ-XFxvlpeNddfLz8vP103YaF4bYQT1sqgg1CgOQK2rTMGgDu17kxn1qazzq4BnLYcOsWcsdaYVhmUzOpOnpAPB99xWm-xDRhrhsGPud9C3vkEvf97EvuNv0n33kkpmTGzwdsng5zuJizVb_sScBggYpqKF9oZbfRCixl98w96m6Yc5_O8MFJZJwxzMyUOVJgfVDJ2v5bhzO9D9YdQ_RyqfwzV77eQB1GZ4XiD-bf1f1Q_AZniogg</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Urso, Luca</creator><creator>Lancia, Federica</creator><creator>Ortolan, Naima</creator><creator>Frapoli, Marta</creator><creator>Rauso, Martina</creator><creator>Artioli, Paolo</creator><creator>Cittanti, Corrado</creator><creator>Uccelli, Licia</creator><creator>Frassoldati, Antonio</creator><creator>Evangelista, Laura</creator><creator>Bartolomei, Mirco</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5117-804X</orcidid></search><sort><creationdate>2022</creationdate><title>18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?</title><author>Urso, Luca ; Lancia, Federica ; Ortolan, Naima ; Frapoli, Marta ; Rauso, Martina ; Artioli, Paolo ; Cittanti, Corrado ; Uccelli, Licia ; Frassoldati, Antonio ; Evangelista, Laura ; Bartolomei, Mirco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-292883c6c25a61eaedd977aa195bf7f7b7f898baa9681af50978877d57e3086f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Choline</topic><topic>Computed tomography</topic><topic>Diagnostic Radiology</topic><topic>Evaluation</topic><topic>Fluorine isotopes</topic><topic>Genitourinary</topic><topic>Imaging</topic><topic>Interventional Radiology</topic><topic>Magnetic resonance imaging</topic><topic>Medical and Radiation Physics</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastasis</topic><topic>Nuclear Medicine</topic><topic>Pictorial</topic><topic>Pictorial Essay</topic><topic>Positron emission</topic><topic>Prostate cancer</topic><topic>Radiology</topic><topic>Radiotherapy</topic><topic>Therapy</topic><topic>Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Urso, Luca</creatorcontrib><creatorcontrib>Lancia, Federica</creatorcontrib><creatorcontrib>Ortolan, Naima</creatorcontrib><creatorcontrib>Frapoli, Marta</creatorcontrib><creatorcontrib>Rauso, Martina</creatorcontrib><creatorcontrib>Artioli, Paolo</creatorcontrib><creatorcontrib>Cittanti, Corrado</creatorcontrib><creatorcontrib>Uccelli, Licia</creatorcontrib><creatorcontrib>Frassoldati, Antonio</creatorcontrib><creatorcontrib>Evangelista, Laura</creatorcontrib><creatorcontrib>Bartolomei, Mirco</creatorcontrib><collection>SpringerOpen</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Urso, Luca</au><au>Lancia, Federica</au><au>Ortolan, Naima</au><au>Frapoli, Marta</au><au>Rauso, Martina</au><au>Artioli, Paolo</au><au>Cittanti, Corrado</au><au>Uccelli, Licia</au><au>Frassoldati, Antonio</au><au>Evangelista, Laura</au><au>Bartolomei, Mirco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready?</atitle><jtitle>Clinical and translational imaging : reviews in nuclear medicine and molecular imaging</jtitle><stitle>Clin Transl Imaging</stitle><date>2022</date><risdate>2022</risdate><volume>10</volume><issue>6</issue><spage>687</spage><epage>695</epage><pages>687-695</pages><issn>2281-7565</issn><issn>2281-5872</issn><eissn>2281-7565</eissn><abstract>Purpose
During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for the evaluation of response to therapy assessment in PCa, mainly due to the lack of large-scale prospective trials.
Methods
We report the cases of seven patients affected by PCa, in which [18F]F-choline PET (either with computed tomography—CT or magnetic resonance imaging—MR) contributed significantly in the systemic therapy response evaluation.
Results and conclusion
[18F]F-choline PET/CT or PET/MR demonstrated to be a useful imaging modality in the assessment of response to systemic therapy in metastatic PCa patients, irrespective of the stage of disease (either in hormone sensitive and in castrate resistant condition) and the kind of systemic treatment. In most cases, PSA serum values and [18F]F-choline PET showed a synchronous disease evolution after systemic therapy. ADT can alter [18F]F-choline uptake, therefore the time of scan should be correctly planned. Finally, PET/CT with [18F]F-choline is a useful tool for reinforcing the identification of metastatic disease in case of a switch from metastatic castration sensitive to castration resistant PCa.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>35919380</pmid><doi>10.1007/s40336-022-00515-7</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5117-804X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2281-7565 |
| ispartof | Clinical and translational imaging : reviews in nuclear medicine and molecular imaging, 2022, Vol.10 (6), p.687-695 |
| issn | 2281-7565 2281-5872 2281-7565 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9333077 |
| source | SpringerLINK Journals |
| subjects | Choline Computed tomography Diagnostic Radiology Evaluation Fluorine isotopes Genitourinary Imaging Interventional Radiology Magnetic resonance imaging Medical and Radiation Physics Medical imaging Medicine Medicine & Public Health Metastasis Nuclear Medicine Pictorial Pictorial Essay Positron emission Prostate cancer Radiology Radiotherapy Therapy Tomography |
| title | 18F-Choline PET/CT or PET/MR and the evaluation of response to systemic therapy in prostate cancer: are we ready? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T16%3A14%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=18F-Choline%20PET/CT%20or%20PET/MR%20and%20the%20evaluation%20of%20response%20to%20systemic%20therapy%20in%20prostate%20cancer:%20are%20we%20ready?&rft.jtitle=Clinical%20and%20translational%20imaging%20:%20reviews%20in%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Urso,%20Luca&rft.date=2022&rft.volume=10&rft.issue=6&rft.spage=687&rft.epage=695&rft.pages=687-695&rft.issn=2281-7565&rft.eissn=2281-7565&rft_id=info:doi/10.1007/s40336-022-00515-7&rft_dat=%3Cproquest_pubme%3E2697676462%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2735892709&rft_id=info:pmid/35919380&rfr_iscdi=true |